The 6 most recent market catalysts affecting $HROW, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 65
Leerink Partners Initiates Coverage On Harrow with Outperform Rating, Announces Price Target of $45
Leerink Partners' analyst Daniel Clark has initiated coverage on Harrow (HROW) with an 'Outperform' rating and a $45 price target. This event is significant for Harrow as it introd…
Aug 21, 2026
Corporate Catalyst
Bullish
Impact 75
Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half
Harrow Inc. released compelling clinical data demonstrating that its IHEEZO ophthalmic gel significantly reduces discomfort for patients undergoing intravitreal injections, a commo…
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 75
Harrow Reports Statistically Significant Results Favoring IHEEZO In Intravitreal Injection Study
Harrow reported statistically significant positive results for its IHEEZO ophthalmic gel in a clinical study. The study demonstrated IHEEZO reduced patient discomfort by approximat…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 92
Harrow Q2 EPS $(0.46) Misses $(0.21) Estimate, Sales $70.661M Beat $70.342M Estimate
Harrow's Q2 earnings per share (EPS) of $(0.46) significantly missed the analyst consensus estimate of $(0.21), representing a 119.05% miss and a 453.85% decrease from the prior ye…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Harrow Announces Agreement To Acquire Dry Eye Nasal Spray TYRVAYA From Viatris For $30M Cash At Closing, Up To $70M In Sales Milestones
This acquisition is a significant corporate catalyst for Harrow, immediately expanding its product offerings in the ophthalmology space with a branded dry eye treatment. The upfron…
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 65
Samsung Bioepis, Harrow Present SB11 Safety Data At ASRS 2026 Annual Meeting; Interim PMS Study Shows SB11 Comparable To Lucentis
Samsung Bioepis and Harrow presented interim post-marketing surveillance (PMS) data for SB11 (BYOOVIZ® / AMELIVU®), a biosimilar referencing Lucentis, at a major ophthalmology conf…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.